Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.

@article{Bellmunt2008TemsirolimusSP,
  title={Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.},
  author={Joaquim Bellmunt and Cezary A. Szczylik and Jay Feingold and Andrew Louis Strahs and Anna Berkenblit},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 8},
  pages={1387-92}
}
BACKGROUND Temsirolimus, a novel inhibitor of mammalian target of rapamycin, has demonstrated prolonged overall survival and progression-free survival compared with interferon alfa (IFN) in patients with advanced renal cell carcinoma (RCC) and poor prognostic features. Adverse events (AEs) of any causality were previously reported, but AEs that were deemed temsirolimus related are of particular relevance for poor-risk patients and for defining mammalian target of rapamycin inhibitor-specific… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 76 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus

  • D DelBufalo, L Ciuffreda, D Trisciuoglio
  • Cancer Res
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…